Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC)
Abstract
Abstract Retrospective characterization of cell-cell relationships in the tumor microenvironment provides significantly better predictive power than PD-L1 expression, tumor mutational burden (TMB), or gene expression profiles. In this small study assessing the safety and possible efficacy of gemcitabine and pembrolizumab in immunotherapy-naïve patients with NSCLC who have received prior treatment, we investigated both standard and novel immune parameters on 16 enrolled patients. The combination of gemcitabine and pembrolizumab could be administered safely but did not demonstrate synergism compared with historical controls. Novel findings of this study are that elevated frequencies of Tregulatory cells near CD3 T cells at baseline was associated with improved outcome to treatment (p
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Cancer
Stress
Anesthesia
and Immune Response
Cytokine Signaling Pathways and Interactions
Publication details
- Journal / source
- OncoImmunology
- Publisher
- Informa UK Limited
- Volume
- 15
- Issue
- 1
- Pages
- 2661444–2661444
- Publication date
- 13 May 2026
- Language
- EN